Investing

Pharma Momentum Fuels Johnson & Johnson’s Path to Double-Digit Upside

Our Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) 24/7 Wall St. price target lands at $261.72, pointing to 11.28% upside from the current price of $235.18. Our recommendation is buy, and our model carries a 90% confidence level. JNJ…

By Vandita Jadeja

Published June 21, 2026, 10:30am ET · 3 min read

A white corporate sign for 'Johnson & Johnson' in red script, with 'MEDICAL DEVICES COMPANIES' in gray text below it. A thin red line is at the bottom of the sign. The sign is outdoors on a sunny day, with a lens flare on the left, trees in the background, and out-of-focus buildings and a street light on the right. — The Johnson & Johnson corporate sign stands as its stock nears a 52-week high. Investors are closely watching for clarity on the company's future market direction. © Mario Tama / Getty Images News via Getty Images

Our Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) 24/7 Wall St. price target lands at $261.72, pointing to 11.28% upside from the current price of $235.18. Our recommendation is buy, and our model carries a 90% confidence level. JNJ has quietly become one of healthcare’s most reliable compounders again, with oncology firing and dividend support intact.

Metric	Value
Current Price	$235.18
24/7 Wall St. Price Target	$261.72
Upside	11.28%
Recommendation	BUY
Confidence Level	90%

A Quiet Rally Into New Highs

JNJ has run hard. Shares are up 14.91% year to date and 55.3% over the past year, currently trading about 1% below the 52-week high of $250.24. The latest Q1 2026 earnings report backed the move. Revenue rose 9.9% to $24.062 billion, and adjusted EPS of $2.70 beat estimates for the fourth consecutive quarter.

Management raised 2026 guidance to $100.3B to $101.3B in sales and $11.45 to $11.65 in adjusted EPS. Recent catalysts include a $1 billion Vision manufacturing expansion in Jacksonville, the $1 billion Firefly Bio acquisition adding a degrader-antibody-conjugate platform, and a Talvey late-stage trial showing up to 53% mortality risk reduction in multiple myeloma.

An infographic titled 'JNJ • JOHNSON & JOHNSON 12-MONTH PRICE PREDICTION'. The top section, 'THE CALL', shows the Current Price of $235.18 leading to a Final Target of $261.72, indicating an +11.28% UPSIDE, with a 'BUY' recommendation and '90% Confidence Level'. The 'HOW WE GOT THERE' section shows a 'WEIGHTED BASE PRICE' bar chart for Trailing P/S Base ($235.18), Forward P/E Base ($233.11), Analyst Target ($252.87), and FINAL WEIGHTED BASE ($239.45). This is adjusted by a '247FACTOR ADJUSTMENT (1.093x)' table, listing Sector Momentum (Healthcare) 1.1x Multiplier, Analyst Consensus (63% Bullish) +0.035, Earnings Growth (-52.9% YoY) -0.03, Volatility (Beta 0.26) +0.015, and Price Position (Near Highs) +0.015, all leading to a FINAL TARGET of $261.72. The 'OUR ADJUSTMENTS' section confirms BASE PRICE: $239.45, with (None) for Market Sentiment and Geopolitical factors, and a '+ 247 WALL ST: 1.093x Factor (+9.3%)' leading to FINAL TARGET: $261.72. A 'BULL CASE: WHAT COULD GO RIGHT' section lists Oncology Surge, MedTech Growth, and Strategic Growth, with a BULL CASE TARGET: $273.48 (+16.28%). A 'BEAR CASE: WHAT COULD GO WRONG' section lists STELARA Erosion, Litigation Headwinds, and IMBRUVICA Decline, with a BEAR CASE TARGET: $222.46 (-5.41%). The 'THE BOTTOM LINE' section states a 'BUY RECOMMENDATION: $261.72 (+11.28% UPSIDE)' and a description of JNJ.

Why Bulls See a Breakout Toward $275

The bull case rests on oncology and immunology firing simultaneously. DARZALEX hit $3.964 billion (+22.5%), TREMFYA reached $1.608 billion (+68.3%), CARVYKTI grew 62.1%, and RYBREVANT/LAZCLUZE jumped 82.7%. Cardiovascular MedTech grew 13.0% on Abiomed and Shockwave.

The analyst consensus target of $252.87 sits between our base and our bull case of $273.48 over the next year. If the DePuy Synthes orthopaedics spin lifts the remaining mix toward double-digit growth, the multiple can expand from the current forward P/E of 20x.

The Risks Worth Watching

The bear case is real. STELARA fell 59.7% in Q1 on biosimilars, dragging Innovative Medicine by roughly 920 basis points. Litigation charges of $330 million in Q1 followed $854 million in Q4 2025, and talc cases remain an overhang.

Our bear scenario lands at $222.46, a 5.41% drawdown. That said, bulls would argue the headline net income decline of 52.4% reflects those non-recurring legal charges rather than underlying operating performance, where adjusted EPS still grew and guidance was raised.

Our Take on JNJ Here

The 24/7 Wall St. price target of $261.72 and buy rating reflect a balanced setup: defensive characteristics, accelerating top-line growth, and a pipeline that should outrun the STELARA cliff. The setup favors investors seeking healthcare exposure with a 0.26 beta and a 64-year dividend growth streak.

The case weakens if talc litigation reserves expand materially or if the orthopaedics separation slips beyond the 18 to 24 month window. Our 90% confidence is high for a reason: this is a low-volatility blue chip with a clear growth narrative.

JNJ Price Prediction 2026-2030

Looking further out, here is where our model projects Johnson & Johnson could trade, assuming current growth trajectories and the planned orthopaedics separation execute on schedule.

Year	24/7 Wall St. Price Target
2026	$248.24
2027	$273.86
2028	$294.53
2029	$315.88
2030	$333.63

These projections assume JNJ continues executing on oncology and cardiovascular MedTech. Significant upside or downside could result from talc litigation outcomes or the pace of double-digit growth promised by end of decade.

Contact [email protected] for any questions or corrections.

Vandita Jadeja

Vandita Jadeja is a financial copywriter who loves to read and write about stocks. She believes in buying and holding for long term gains. Her knowledge of words and numbers helps her write clear stock analysis. She has contributed to several publications, including the Joy Wallet, Benzinga, The Motley Fool and InvestorPlace.

All articles →